carbidopa
FDA Approves Vyalev: A Breakthrough Continuous Infusion Therapy for Advanced Parkinson’s Disease
Vyalev, Parkinson’s disease, continuous infusion therapy, FDA approval, AbbVie, motor fluctuations, levodopa, carbidopa
AbbVie’s Duopa Successor in Parkinson’s Rejected Again Due to Third-Party Manufacturer Issues
AbbVie, Duopa, Parkinson’s disease, FDA rejection, third-party manufacturer, ABBV-951, carbidopa, levodopa, subcutaneous pump device